Sacituzumab tirumotecan: previously treated triple-negative breast cancerAfter several treatment lines,
seek another chance of tumour shrinkage.
If triple-negative breast cancer continues to progress after several treatments and sacituzumab tirumotecan is difficult to obtain locally, China has a routine prescription pathway for eligible patients. It offers an opportunity to delay progression and shrink tumours in later-line treatment, provided prior-treatment requirements are met and hospital supply and ongoing infusions are arranged.
Free initial service consultation · Understand your options and budget before you travel
- Median progression-free survival
- 6.7 months versus 2.5 months
- Objective response rate
- 45.4% versus 12.0%
The comparator was physician's choice of chemotherapy; this does not establish superiority to other ADCs or support use in untreated triple-negative breast cancer. View the evidence
Efficacy comes from OptiTROP-Breast01 against physician's choice of chemotherapy and cannot rank different ADCs. Drug prices come from Tungwah's publication on 2026-06-26, not current international patient quotes or full treatment costs. View sources
Access a suitable new ADC after several treatment lines
If sacituzumab tirumotecan is not readily available locally, patients meeting the Chinese indication can discuss routine prescribing as part of their next treatment plan.
Access need not depend solely on clinical trial eligibility
China has an approved pathway for this drug. Eligible patients can discuss routine treatment, while actual patient acceptance, stock and prescriptions still require hospital confirmation.
Use your treatment history to help choose the next step
Review prior immunotherapy, chemotherapy and ADC exposure to assess whether later-line study findings apply to you. Resistance to one ADC does not mean a different ADC will necessarily work.
Example for 60kg: RMB 9,100 in drug costs per administration; budget for continued treatment
Estimated for fully self-funded foreign patients without Chinese health insurance or free-drug assistance. The example below calculates only drug costs using whole 200mg vials. Include infusions, blood tests and supportive medicines when planning a budget for treatment every two weeks.
- 200mg × 1 vial
- RMB 4,550
- Example: 60kg at 5mg/kg
- 300mg required; using only whole 200mg vials, 2 vials cost RMB 9,100 per administration
- Infusions, blood tests and supportive medicines
- Itemised confirmation from the hospital is needed
Published by Tungwah on 2026-06-26; not an international patient quote. Usual dosing is every 2 weeks. The example includes unused medicine from whole vials; confirm actual costs using available strengths and the prescription.
Finding treatment that fits you
starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
- Pathology requirementsAdults with unresectable locally advanced or metastatic triple-negative breast cancer; review ER, PR and HER2.
- Treatment requirementsConfirm at least two systemic treatments, including treatment in the advanced setting; recurrence alone is insufficient.
- Health requirementsBlood counts, liver and kidney function and oral health must permit treatment; previous ADC resistance requires additional assessment.
After several treatment lines, seek to delay progression and shrink tumours
OptiTROP-Breast01, published in Nature Medicine in 2025, compared this drug with physician's choice of chemotherapy and observed progression-free survival and tumour response benefits. This does not establish superiority to other ADCs.
- Hazard ratio for progression or death
- 0.32 (95% confidence interval 0.24–0.44)
- Main safety concerns
- Bone marrow suppression, oral mucositis and nausea
- Randomised enrolment
- 263 patients
Benefit varies between individuals. Treatment continues until progression or unacceptable toxicity, and reassessment may lead to delays or dose reductions.
You do not need to book flights first.
Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
- Bring initial and recurrence pathology with ER/PR/HER2 results to confirm the triple-negative subtype
- List all systemic treatments, dates and progression evidence to verify prior treatment lines
- Provide recent imaging and brain metastasis assessment records to establish current disease status
- Prepare blood counts, liver and kidney function and records of oral problems to plan treatment and supportive care
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you
before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
Can I use it simply because disease progressed after several treatments?
You must also meet requirements including adult unresectable locally advanced or metastatic triple-negative breast cancer and at least two prior systemic treatments, at least one for advanced or metastatic disease. Physical tolerance and previous ADC resistance must be assessed.
Is it the same medicine as sacituzumab govitecan?
No. Their payloads and studies differ. Doses and efficacy cannot be interchanged, and this study cannot rank the two medicines.
Which symptoms require prompt contact with the hospital?
Contact the hospital promptly for fever, significant bleeding, mouth pain affecting eating or persistent vomiting, to assess infection, bone marrow suppression and supportive treatment needs.
Can I return home after one infusion and continue treatment there?
Treatment every two weeks, blood tests and ongoing drug supply must first be arranged. Treatment usually continues until progression or unacceptable toxicity; reassessment may cause delays or dose reductions. A single infusion is not a substitute for a continuous treatment plan.
Turn your next treatment step into a concrete plan.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Sources and image credits
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
- Kelun-Biotech: product and approved Chinese indications · Verified 2026-10-03
- Nature Medicine: original OptiTROP-Breast01 paper · 2025-04-11
- Kelun-Biotech: sacituzumab tirumotecan prescribing information · 2024-11-22
- Dongguan Tungwah Hospital drug price publication (original official table) · 2026-06-26
- Cancer Hospital, Chinese Academy of Medical Sciences: Xu Binghe · Verified 2026-10-03